Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferences:
|
Morgan Stanley Global Healthcare Conference |
|
Date: Tuesday, September 14, 2010 |
||
Time: 10:55am Eastern Time (7:55am Pacific Time) |
||
Place: Grand Hyatt Hotel in New York City |
||
Speaker: Ted Schroeder, President & CEO |
||
|
Stifel Nicolaus Healthcare Conference 2010 |
|
Date: Thursday, September 16, 2010 |
||
Time: 8:00am Eastern Time (5:00am Pacific Time) |
||
Place: Four Seasons Hotel in Boston |
||
Speaker: Ted Schroeder, President & CEO |
||
|
UBS Global Life Sciences Conference |
|
Date: Wednesday, September 22, 2010 |
||
Time: 10:00am Eastern Time (7:00am Pacific Time) |
||
Place: Grand Hyatt Hotel in New York City |
||
Speaker: William R. LaRue, SVP & CFO |
||
|
JMP Securities Healthcare Conference |
|
Date: Monday, September 27, 2010 |
||
Time: 10:00am Eastern Time (7:00am Pacific Time) |
||
Place: The New York Palace Hotel in New York City |
||
Speaker: Ted Schroeder, President & CEO |
||
Each presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com on the Investor Relations page. A replay of each webcast will available approximately three hours after the live webcast concludes and will remain available for 30 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. For more information about Cadence, visit www.cadencepharm.com.
Contacts: |
William R. LaRue SVP, CFO Cadence Pharmaceuticals, Inc. 858-436-1400 |
|
SOURCE Cadence Pharmaceuticals, Inc.
Share this article